C-type lectin-like receptor-2 (CLEC-2) is a member of the C-type lectin superfamily of cell surface receptors. The first confirmed endogenous and exogenous ligands of CLEC-2 are podoplanin and rhodocytin, respectively. CLEC-2 is expressed on the surface of platelets, which participates in platelet activation and aggregation by binding with its ligands. CLEC-2 and its ligands are involved in pathophysiological processes, such as atherosclerosis, cancer, inflammatory thrombus status, maintenance of vascular wall integrity, and cancer-related thrombosis. In the last 5 years, different anti- podoplanin antibody types have been developed for the treatment of cancers, such as glioblastoma and lung cancer. New tests and new diagnostics targeting CLEC-2 are also discussed. CLEC-2 mediates thrombosis in various pathological states, but CLEC-2-specific deletion does not affect normal hemostasis, which would provide a new therapeutic tool for many thromboembolic diseases. The CLEC-2-podoplanin interaction is a target for cancer treatment. CLEC-2 may be applied in clinical practice and play a therapeutic role.

中文翻译：

---

C型凝集素样受体2：作用和药物靶点

C 型凝集素样受体-2 (CLEC-2) 是细胞表面受体 C 型凝集素超家族的成员。第一个被证实的 CLEC-2 内源性和外源性配体分别是足足蛋白 (podoplanin) 和蛇形细胞素 (rhodocytin)。CLEC-2表达于血小板表面，通过与其配体结合参与血小板活化和聚集。CLEC-2及其配体参与病理生理过程，例如动脉粥样硬化、癌症、炎性血栓状态、血管壁完整性的维持以及癌症相关的血栓形成。在过去 5 年中，不同类型的抗足足蛋白抗体类型已被开发用于治疗癌症，例如胶质母细胞瘤和肺癌。还讨论了针对 CLEC-2 的新测试和新诊断。CLEC-2在多种病理状态下介导血栓形成，但CLEC-2特异性缺失并不影响正常止血，这将为许多血栓栓塞性疾病提供新的治疗工具。CLEC-2-podoplanin 相互作用是癌症治疗的靶点。CLEC-2可能应用于临床并发挥治疗作用。